P
Paraskevi Salpea
Researcher at International Diabetes Federation
Publications - 5
Citations - 5474
Paraskevi Salpea is an academic researcher from International Diabetes Federation. The author has contributed to research in topics: Diabetes mellitus & Internal medicine. The author has an hindex of 3, co-authored 3 publications receiving 2221 citations.
Papers
More filters
Journal ArticleDOI
Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition.
Pouya Saeedi,Inga Petersohn,Paraskevi Salpea,Belma Malanda,Suvi Karuranga,Nigel Unwin,Stephen Colagiuri,Leonor Guariguata,Ayesha A. Motala,Katherine Ogurtsova,Jonathan E. Shaw,Dominic Bright,Rhys Williams +12 more
TL;DR: Just under half a billion people are living with diabetes worldwide and the number is projected to increase by 25% in 2030 and 51% in 2045, with the prevalence higher in urban than rural areas, and in high-income than low-income countries.
Journal ArticleDOI
Mortality attributable to diabetes in 20-79 years old adults, 2019 estimates: Results from the International Diabetes Federation Diabetes Atlas, 9th edition.
Pouya Saeedi,Paraskevi Salpea,Suvi Karuranga,Inga Petersohn,Belma Malanda,Edward W. Gregg,Nigel Unwin,Sarah H. Wild,Rhys Williams +8 more
TL;DR: Prevention of diabetes and its complications is essential, particularly in middle-income countries, where the current impact is estimated to be the largest.
Journal ArticleDOI
Worldwide estimates of incidence, prevalence and mortality of type 1 diabetes in children and adolescents: Results from the International Diabetes Federation Diabetes Atlas, 9th edition.
Christopher Patterson,Suvi Karuranga,Paraskevi Salpea,Pouya Saeedi,Gisela Dahlquist,Gyula Soltész,Graham D. Ogle +6 more
TL;DR: Worldwide estimates of numbers of children and adolescents with type 1 diabetes continue to increase, but prevalence estimates have decreased in the sub-Saharan Africa because allowance has been made for increased mortality in those with diabetes.
Journal ArticleDOI
GLP-1R agonists demonstrate potential to treat Wolfram syndrome in human preclinical models
Vyron A. Gorgogietas,Bahareh Rajaei,Cha Heeyoung,Bruno Jaime Santacreu,Sandra Marín-Cañas,Paraskevi Salpea,Toshiaki Sawatani,Anyishaï Musuaya,María Nicol Arroyo,Cristina Moreno-Castro,Céline Demarez,Sanna Charlotta Toivonen,Cristina Cosentino,Nathalie Pachera,Maria Lytrivi,Chris Cb Brown,Fumihiko Urano,Piero Marchetti,Patrick Gilon,Decio L. Eizirik,Miriam Cnop,Mariana Igoillo-Esteve +21 more
TL;DR: In this paper , the effect of glucagon-like peptide 1 receptor (GLP-1R) agonists under wolframin (WFS1) deficiency with a particular focus on human beta cells and neurons was examined in Wfs1 knockout mice and in an array of human preclinical models of Wolfram syndrome.